A Second Life for MAP, a Model Amphipathic Peptide

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Aug 12

PMID 35955457

Authors

Sara Silva

Kaido Kurrikoff

Ulo Langel

Antonio J Almeida

Nuno Vale

Affiliations

Soon will be listed here.

Abstract

Cell-penetrating peptides (CPP) have been shown to be efficient in the transport of cargoes into the cells, namely siRNA and DNA, proteins and peptides, and in some cases, small therapeutics. These peptides have emerged as a solution to increase drug concentrations in different tissues and various cell types, therefore having a relevant therapeutic relevance which led to clinical trials. One of them, MAP, is a model amphipathic peptide with an α-helical conformation and both hydrophilic and hydrophobic residues in opposite sides of the helix. It is composed of a mixture of alanines, leucines, and lysines (KLALKLALKALKAALKLA). The CPP MAP has the ability to translocate oligonucleotides, peptides and small proteins. However, taking advantage of its unique properties, in recent years innovative concepts were developed, such as in silico studies of modelling with receptors, coupling and repurposing drugs in the central nervous system and oncology, or involving the construction of dual-drug delivery systems using nanoparticles. In addition to designs of MAP-linked vehicles and strategies to achieve highly effective yet less toxic chemotherapy, this review will be focused on unique molecular structure and how it determines its cellular activity, and also intends to address the most recent and frankly motivating issues for the future.

Citing Articles

Advances and prospects of cell-penetrating peptides in tumor immunotherapy.

Yang D, Liu B, Sha H Sci Rep. 2025; 15(1):3392.

PMID: 39870681 PMC: 11772771. DOI: 10.1038/s41598-025-86130-8.

Peptides as Versatile Regulators in Cancer Immunotherapy: Recent Advances, Challenges, and Future Prospects.

Lei Y, Liu J, Bai Y, Zheng C, Wang D Pharmaceutics. 2025; 17(1).

PMID: 39861694 PMC: 11768547. DOI: 10.3390/pharmaceutics17010046.

Computational Insights into Membrane Disruption by Cell-Penetrating Peptides.

Catalina-Hernandez E, Aguilella-Arzo M, Peralvarez-Marin A, Lopez-Martin M J Chem Inf Model. 2025; 65(3):1549-1559.

PMID: 39823544 PMC: 11815844. DOI: 10.1021/acs.jcim.4c01940.

A Cell-Penetrating Peptide Improves Anti-HER2 Single-Chain Variable Fragment Internalization and Antitumor Activity against HER2-Positive Breast Cancer In Vitro and In Vivo.

Li J, Zhou Y, Su Z, Li X, Zhang L, Li S Molecules. 2024; 29(6).

PMID: 38542884 PMC: 10974526. DOI: 10.3390/molecules29061247.

Cell-Penetrating Peptides (CPPs) as Therapeutic and Diagnostic Agents for Cancer.

Bottens R, Yamada T Cancers (Basel). 2022; 14(22).

PMID: 36428639 PMC: 9688740. DOI: 10.3390/cancers14225546.

References

Borrelli A, Tornesello A, Tornesello M, Buonaguro F . Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents. Molecules. 2018; 23(2). PMC: 6017757. DOI: 10.3390/molecules23020295. View

Wada S, Hashimoto Y, Kawai Y, Miyata K, Tsuda H, Nakagawa O . Effect of Ala replacement with Aib in amphipathic cell-penetrating peptide on oligonucleotide delivery into cells. Bioorg Med Chem. 2013; 21(24):7669-73. DOI: 10.1016/j.bmc.2013.10.029. View

Pierige F, Serafini S, Rossi L, Magnani M . Cell-based drug delivery. Adv Drug Deliv Rev. 2007; 60(2):286-95. DOI: 10.1016/j.addr.2007.08.029. View

Janek K, Rothemund S, Gast K, Beyermann M, Zipper J, Fabian H . Study of the conformational transition of A beta(1-42) using D-amino acid replacement analogues. Biochemistry. 2001; 40(18):5457-63. DOI: 10.1021/bi002005e. View

Bocsik A, Walter F, Gyebrovszki A, Fulop L, Blasig I, Dabrowski S . Reversible Opening of Intercellular Junctions of Intestinal Epithelial and Brain Endothelial Cells With Tight Junction Modulator Peptides. J Pharm Sci. 2016; 105(2):754-765. DOI: 10.1016/j.xphs.2015.11.018. View

Croce N, Ciotti M, Gelfo F, Cortelli S, Federici G, Caltagirone C . Neuropeptide Y protects rat cortical neurons against β-amyloid toxicity and re-establishes synthesis and release of nerve growth factor. ACS Chem Neurosci. 2012; 3(4):312-8. PMC: 3369802. DOI: 10.1021/cn200127e. View

Deli M . Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta. 2008; 1788(4):892-910. DOI: 10.1016/j.bbamem.2008.09.016. View

Regberg J, Srimanee A, Erlandsson M, Sillard R, Dobchev D, Karelson M . Rational design of a series of novel amphipathic cell-penetrating peptides. Int J Pharm. 2014; 464(1-2):111-6. DOI: 10.1016/j.ijpharm.2014.01.018. View

Silva S, Alves C, Duarte D, Costa A, Sarmento B, Almeida A . Model Amphipathic Peptide Coupled with Tacrine to Improve Its Antiproliferative Activity. Int J Mol Sci. 2021; 22(1). PMC: 7795729. DOI: 10.3390/ijms22010242. View

10.

Chen S, Eiting K, Cui K, Leonard A, Morris D, Li C . Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery. J Pharm Sci. 2006; 95(6):1364-71. DOI: 10.1002/jps.20510. View

11.

Reissmann S . Cell penetration: scope and limitations by the application of cell-penetrating peptides. J Pept Sci. 2014; 20(10):760-84. DOI: 10.1002/psc.2672. View

12.

Silva S, Marto J, Goncalves L, Duarte D, Soares O, Vasques-Novoa F . New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity. Int J Mol Sci. 2022; 23(13). PMC: 9266917. DOI: 10.3390/ijms23137109. View

13.

Johnson P, Quay S . Advances in nasal drug delivery through tight junction technology. Expert Opin Drug Deliv. 2005; 2(2):281-98. DOI: 10.1517/17425247.2.2.281. View

14.

Lindgren M, Langel U . Classes and prediction of cell-penetrating peptides. Methods Mol Biol. 2010; 683:3-19. DOI: 10.1007/978-1-60761-919-2_1. View

15.

Frankel A, Pabo C . Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988; 55(6):1189-93. DOI: 10.1016/0092-8674(88)90263-2. View

16.

Lindgren M, Hallbrink M, Elmquist A, Langel U . Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem J. 2003; 377(Pt 1):69-76. PMC: 1223834. DOI: 10.1042/BJ20030760. View

17.

Silva S, Marto J, Goncalves L, Fernandes H, Sousa S, Almeida A . Development of Neuropeptide Y and Cell-Penetrating Peptide MAP Adsorbed onto Lipid Nanoparticle Surface. Molecules. 2022; 27(9). PMC: 9101637. DOI: 10.3390/molecules27092734. View

18.

Mager I, Eiriksdottir E, Langel K, El Andaloussi S, Langel U . Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay. Biochim Biophys Acta. 2009; 1798(3):338-43. DOI: 10.1016/j.bbamem.2009.11.001. View

19.

Fotin-Mleczek M, Welte S, Mader O, Duchardt F, Fischer R, Hufnagel H . Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization. J Cell Sci. 2005; 118(Pt 15):3339-51. DOI: 10.1242/jcs.02460. View

20.

Leuschner C, Hansel W . Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des. 2004; 10(19):2299-310. DOI: 10.2174/1381612043383971. View